73 filings
Page 2 of 4
DEFA14A
2navu15ew b452
19 Apr 23
Additional proxy soliciting materials
4:31pm
ARS
0bp3tvh4030lizah
19 Apr 23
Annual report to shareholders
4:29pm
8-K
ix8j5avk638lk
5 Apr 23
Entry into a Material Definitive Agreement
4:32pm
424B5
3m9wldth dcuv
5 Apr 23
Prospectus supplement for primary offering
4:30pm
S-8
0vk5 ws1lmvd3lgo
29 Mar 23
Registration of securities for employees
5:10pm
8-K
gr0t s6admh1x4c
29 Mar 23
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
4:52pm
8-K
8e8t6
23 Jan 23
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
8:01am
8-K
zkbp4zfmml8rlsos12
14 Nov 22
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
7:46am
EFFECT
kcg38q0
24 Aug 22
Notice of effectiveness
12:15am
CORRESP
skychl7t
19 Aug 22
Correspondence with SEC
12:00am
UPLOAD
shcxxlnz0q305oa50r1g
18 Aug 22
Letter from SEC
12:00am
S-3
uq251ncem18ns
15 Aug 22
Shelf registration
6:00pm
8-K
cd9w5
15 Aug 22
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
7:55am
8-K
4bw6me7m6dj
22 Jun 22
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
53rgypwa9hekv0g5
16 May 22
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
8:00am